Phase IIb data scratch the itch for Creabilis
This article was originally published in Scrip
Executive Summary
Creabilis has reported positive Phase IIb data from with its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, in psoriasis patients, although not all study endpoints were met.
You may also be interested in...
Itch-Focused Creabilis Finally Secures Its Future Through US Sale
Creabilis has finally secured the future of its Phase III-ready psoriatic itch candidate CT327 – through a sale of the company to young US firm Sienna Biopharmaceuticals.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.